Compounds > lucilactaene

Page last updated: 2024-11-12

lucilactaene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lucilactaene: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	9909017
CHEMBL ID	5072627
MeSH ID	M0411234

Synonyms (3)

Synonym
methyl (2e,3e,5e,7e,9e)-11-[(3as,6s,6ar)-3a-hydroxy-5-oxo-3,4,6,6a-tetrahydro-2h-furo[3,2-b]pyrrol-6-yl]-2-ethylidene-4,10-dimethyl-11-oxoundeca-3,5,7,9-tetraenoate
lucilactaene
CHEMBL5072627

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay ID	Title	Year	Journal	Article
AID1818764	Antimalarial activity against wild-type Plasmodium falcipuram 3D7 assessed as growth inhibition	2022	Journal of natural products, 01-28, Volume: 85, Issue:1	Dihydrolucilactaene, a Potent Antimalarial Compound from
AID1818755	Cytotoxicity against human HeLa cells assessed as growth inhibition	2022	Journal of natural products, 01-28, Volume: 85, Issue:1	Dihydrolucilactaene, a Potent Antimalarial Compound from
AID1818761	Antifungal activity against Aspergillus fumigatus Af293 assessed as growth inhibition	2022	Journal of natural products, 01-28, Volume: 85, Issue:1	Dihydrolucilactaene, a Potent Antimalarial Compound from
AID1818763	Antifungal activity against Candida albicans JCM1542 assessed as growth inhibition	2022	Journal of natural products, 01-28, Volume: 85, Issue:1	Dihydrolucilactaene, a Potent Antimalarial Compound from
AID1818756	Cytotoxicity against human HL-60 cells assessed as growth inhibition	2022	Journal of natural products, 01-28, Volume: 85, Issue:1	Dihydrolucilactaene, a Potent Antimalarial Compound from
AID1818762	Antifungal activity against Pyricularia oryzae kita-1 assessed as growth inhibition	2022	Journal of natural products, 01-28, Volume: 85, Issue:1	Dihydrolucilactaene, a Potent Antimalarial Compound from
AID1818760	Antibacterial activity against Escherichia coli HO141 assessed as growth inhibition	2022	Journal of natural products, 01-28, Volume: 85, Issue:1	Dihydrolucilactaene, a Potent Antimalarial Compound from
AID1818759	Antibacterial activity against Staphylococcus aureus 209 assessed as growth inhibition	2022	Journal of natural products, 01-28, Volume: 85, Issue:1	Dihydrolucilactaene, a Potent Antimalarial Compound from
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (44.44)	29.6817
2010's	0 (0.00)	24.3611
2020's	5 (55.56)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.36 (24.57)
Research Supply Index	2.30 (2.92)
Research Growth Index	4.66 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.36)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (11.11%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (88.89%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	2.41	1	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	4.67	8	0	pyrrole; secondary amine
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.41	1	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
artemisinin (+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	2.41	1	0	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite
reveromycin a reveromycin A: from an actinomycete strain; structure given in first source; inhibits the mitogenic activity of the epidermal growth factor	3.11	1	0
phosmidosine phosmidosine: from Streptomyces sp. RK-16; structure given in first source	3.11	1	0
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	2.25	1	0
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	2.41	1	0	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
antibiotic 1233a antibiotic 1233A: beta-lactone antibiotic from Cephalosporium; hydroxymethylglutaryl-CoA synthase & 3C protease, viral inhibitor; structure in first source	2.25	1	0	long-chain fatty acid
tryprostatin a tryprostatin A: isolated from Aspergillus fumigatus; a mammalian cell cycle inhibitor; structure given in first source. tryprostatin A : A cyclic dipeptide that is brevianamide F (cyclo-L-Trp-L-Pro) substituted at positions 2 and 6 on the indole ring by prenyl and methoxy groups respectively.	3.11	1	0	aromatic ether; dipeptide; indole alkaloid; indoles; pyrrolopyrazine	breast cancer resistance protein inhibitor
terpendole e terpendole E: structure in first source	3.11	1	0	organic heterotricyclic compound; organooxygen compound
hygromycin b [no description available]	2.25	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Innate Inflammatory Response [description not available]	0	2.25	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.25	1	0